Unlocking DOE potential selecting the most appropriate design for rAAV optimization
Konstantina TzimouiD, David Catalán-TatjeriD, Lars Keld NielseniD, Jesús Lavado‐GarcíaiD
Abstract
The production of recombinant adeno-associated virus (rAAV) for gene therapy via triple transfection is a highly intricate process involving many cellular interactions. Each of the different elements encoded in the three required plasmids--pHelper, pRepCap, and pGOI-- play a distinct role and affect different cellular pathways when producing rAAVs. The expression balance of these different elements emphasizes the critical need to fine-tune the concentration of all three plasmids and transfection reagents effectively. The use of design of experiments (DOE) to find optimal plasmid and transfection reagent ratios is a powerful method to streamline the process. However, the choice of the DOE method and the design construction is crucial to avoid misleading results. In this work, we examined and compared four distinct DOE approaches: a rotatable central composite design (RCCD), a Box-Behnken design (BBD), a face-centered central composite design (FCCD), and a mixture design (MD). We compared the ability of the different models to predict optimal ratios, interactions among the three plasmids and transfection reagent, and the essentiality of studying the variability caused by uncontrolled random effects using blocking. Our findings revealed that MD, when coupled with FCCD, outperformed all other tested models. This outcome underscores the importance of selecting a model that can effectively account for the biological context, ultimately yielding superior results in optimizing rAAV production.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 14
- FWCI
- 2.93
- Field percentile
- top 8%
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Mechanistic Modeling Explains the Production Dynamics of Recombinant Adeno-Associated Virus with the Baculovirus Expression Vector System
Francesco Destro, John Joseph, … Richard D. Braatz·Molecular Therapy — Methods & Clinical DevelopmentPeer-reviewed·Jun 2, 2023
- Transcriptomics-informed pharmacology identifies epigenetic and cell cycle regulators as enhancers of AAV production
Joshua M. Tworig, Francis Grafton, … Mohammad A. Mandegar·Molecular Therapy — Methods & Clinical DevelopmentPeer-reviewed·Nov 18, 2024
- Reducing encapsidated impurity DNA derived from plasmid backbone by modifying the p5 terminal resolution site in rAAV vector production
Yuya Nishimura, Shoko Hataya, … Naoki Makita·bioRxiv·May 8, 2026
- Popularizing recombinant baculovirus-derived OneBac system for scaling-up production of all recombinant adeno-associated virus vector serotypes
- Improved Genome Packaging Efficiency of AAV Vectors Using Rep Hybrids
Mario Mietzsch, Courtnee Eddington, … Mavis Agbandje‐McKenna·Journal of VirologyPeer-reviewed·Jul 21, 2021
- Wild type AAV, recombinant AAV, and Adenovirus super infection impact on AAV vector mobilization
L. Song, R. J. Samulski, M. L. Hirsch·bioRxiv·May 13, 2020